Hi there!
We track 52,000+ AI startups and surface hidden job opportunities that never appear on LinkedIn. Tell us what you're looking for, our AI agent does the searching. It's free and you sign up using Google. Go explore!
Sensydia
Sensydia is developing the Cardiac Performance System (CPS), a non-invasive, point-of-care hemodynamic measurement platform designed to advance cardiovascular and critical patient care. The CPS…
Sensydia
Sensydia is developing the Cardiac Performance System (CPS), a non-invasive, point-of-care hemodynamic measurement platform designed to advance cardiovascular and critical patient care. The CPS…
TL;DR
Product: Sensydia Cardiac Performance System (CPS) — non-invasive, point-of-care hemodynamic measurement platform
Key metrics: Ejection Fraction (EF), Cardiac Output (CO), Pulmonary Artery Pressure (PAP)
Regulatory/recognition: FDA Breakthrough Device designation (CPS) and FDA-approved EF metric (2018)
Funding signals: NIH grant support including a $3M award and a second phase; announced $8M financing in 2023
About 11 employees